All trials View full record on ClinicalTrials.gov
NCT07367815PHASE1NOT YET RECRUITING
Allogeneic Adipose Tissue Derived-stem Cells in Alzheimer Disease
✨ Plain-English version on the way · ~2 days
We're still translating this one. In a couple of days, you'll see what this trial actually tests — and whether it matters for APOE4 carriers like you. For now, here's the sponsor's own description:
A3D is a phase I/II clinical trial. The primary objective is to evaluate the safety of allogeneic adipose tissue derived-stem cells (AdMSC) administered by intravenous (IV) route in mild to moderate Alzheimer disease (AD) using a dose escalation protocol.Read full record on ClinicalTrials.gov
Eligibility check — Phoenix members
Phoenix members see for THIS trial:
- APOE genotype match
- Cognitive status fits inclusion
- Specific exclusions flagged
- Distance to nearest site
Start
2026-03-01
Interventions tested
- DRUGCellREADY® drug product IV dose of 50 millions
- DRUGCellREADY® drug product IV dose of 100 millions
- DIAGNOSTIC_TESTcerebral RMI
- DIAGNOSTIC_TESTPET scan